Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

5.640 +0.030 (+0.53%)
Streaming Delayed Price Updated: 10:08 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Syros to Participate in Upcoming Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Analyst Expectations for Syros Pharmaceuticals's Future
Via Benzinga
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
From Syros Pharmaceuticals, Inc.
Via Business Wire
Syros Announces Clinical Updates and 2023 Strategic Priorities
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
From Syros Pharmaceuticals
Via Business Wire
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million... 
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Looking Into Syros Pharmaceuticals's Recent Short Interest
Syros Pharmaceuticals's (NASDAQ:SYRS) short percent of float has fallen 48.18% since its last report. The company recently reported that it has 775 thousand shares sold short, which is 4.12% of all... 
Via Benzinga
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week
Investors are still interested in short squeeze stocks lately and we've got them covered with the ones to watch this week! 
Via InvestorPlace
Grenwich LilfeSciences, Blue Apron And 3 More Short Squeeze Candidates That May Soar
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week... 
Via Benzinga
10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.